4889
Renascience Inc.
レナサイエンス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
139,333
Mar 2023
100,545
Mar 2024
194,165
Mar 2025
132,693
Mar 2026
68,554
Operating profit(thousand JPY)
Mar 2022
-210,839
Mar 2023
-333,870
Mar 2024
-252,335
Mar 2025
-178,827
Mar 2026
-356,885
Operating profit margin(%)
Mar 2022
-151.32
Mar 2023
-332.06
Mar 2024
-129.96
Mar 2025
-134.77
Mar 2026
-520.59
Profit before tax(thousand JPY)
Mar 2022
-253,088
Mar 2023
-333,839
Mar 2024
-256,377
Mar 2025
143,763
Mar 2026
-300,272
Profit(thousand JPY)
Mar 2022
-254,292
Mar 2023
-335,797
Mar 2024
-258,335
Mar 2025
113,427
Mar 2026
-301,276
Total assets(thousand JPY)
Mar 2022
2,438,028
Mar 2023
2,274,818
Mar 2024
2,088,833
Mar 2025
1,871,362
Mar 2026
3,503,263
Cash and cash equivalents(thousand JPY)
Mar 2022
2,005,816
Mar 2023
1,831,780
Mar 2024
1,646,193
Mar 2025
1,799,816
Mar 2026
3,402,705
Cash flows from operating activities(thousand JPY)
Mar 2022
-230,492
Mar 2023
-284,641
Mar 2024
-230,519
Mar 2025
-176,342
Mar 2026
-291,307
Cash flows from investing activities(thousand JPY)
Mar 2022
-296
Mar 2023
232
Mar 2024
-1,567
Mar 2025
382,147
Mar 2026
-
Cash flows from financing activities(thousand JPY)
Mar 2022
1,591,662
Mar 2023
110,371
Mar 2024
46,500
Mar 2025
-52,182
Mar 2026
1,894,196
Return on equity(%)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
6.8
Mar 2026
-
Equity ratio(%)
Mar 2022
90.3
Mar 2023
82
Mar 2024
76.9
Mar 2025
91.9
Mar 2026
94.5
Earnings per share(JPY per share)
Mar 2022
-22.33
Mar 2023
-26.42
Mar 2024
-20.32
Mar 2025
8.92
Mar 2026
-23.39
Net assets per share(JPY per share)
Mar 2022
173.14
Mar 2023
146.72
Mar 2024
126.4
Mar 2025
135.32
Mar 2026
240.26
Dividend per share(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Payout ratio(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.